Key Highlights

  • Net loss for the quarter ended September 30, 2026 was USD 2.6 million.
  • Professional fees increased about USD 933 thousand, tied to merger-related expenses.
  • Cash balance was USD 6,486,639 as of September 30, 2026.
  • The proposed Merger with North Immunology has not been completed.

Aethlon Medical (NASDAQ:AEMD) reported a net loss of USD 2.6 million for its fiscal second quarter ended September 30, 2026, against USD 1.5 million in the same quarter a year earlier. The loss per share was USD 2.60, against an estimate of a loss of USD 2.70, and the company reported no revenue. The medical technology company develops the Hemopurifier, a device designed to bind extracellular vesicles and enveloped viruses.

Quarterly Financial Results

Net loss increased by approximately USD 952 thousand, or 29%, from USD 1,487 thousand to approximately USD 2,618 thousand. The company attributed the increase primarily to higher professional fees of approximately USD 790 thousand, general and administrative expenses of approximately USD 88 thousand and Payroll and related expenses of approximately USD 74 thousand.

The company stated that the professional fee increase was primarily attributable to higher legal fees and transaction-related expenses associated with the proposed merger, including fees for a fairness opinion, as well as higher Investor relations fees, partly offset by lower accounting fees. General and administrative expenses increased because the Australian Research and Development tax Credit had not been recognized in the period, partly offset by lower clinical trial costs due to the timing of patient treatments. The company said there can be no assurance it receives the tax credit in the current fiscal year.

Payroll-related expenses increased primarily due to severance costs associated with workforce reductions implemented near the end of the quarter in connection with the potential transition of operations under the proposed merger with North Immunology. Other income, net, was approximately USD 58 thousand, against USD 23 thousand, primarily interest income.

Six-Month Results and Liquidity

For the six months ended September 30, 2026, net loss was USD 4,165 thousand, against USD 3,249 thousand a year earlier. Loss attributable to common stockholders was USD 5.97 per basic and diluted share for the six months, against USD 53.27. Other income was approximately USD 89 thousand, against USD 53 thousand.

As of September 30, 2026, the company had a cash balance of USD 6,486,639 and Working Capital of USD 5,582,635, against USD 5,026,458 and USD 4,122,702 at March 31, 2026. Net cash used in Operating Activities was USD 3.6 million for the six months, against USD 3.4 million, and net cash provided by financing activities was approximately USD 5.1 million, against USD 3.7 million.

Merger and Clinical Update

The company stated it remained operational at quarter-end and retained personnel necessary to continue its ongoing Australian oncology clinical trial. The proposed merger has not been completed and remains subject to applicable closing conditions. The filing refers to the potential monetization of the legacy Hemopurifier Business and any payments under contemplated contingent value rights, and lists the ability to maintain its Nasdaq listing among its risk factors.

The filing states that the Hemopurifier has been evaluated in human studies involving 179 treatment sessions in 46 patients with viral infections or cancer, and that the device was well tolerated with an adverse event profile consistent with extracorporeal therapy.